MS4A1 Antibody

What is MS4A1 and why is it an important research target?

MS4A1 (Membrane Spanning 4-Domains A1), commonly known as CD20, is a 30-33 kDa non-glycosylated protein expressed on the surface of B lymphocytes. It functions as a calcium channel component that regulates B-cell development, differentiation, and activation . The importance of MS4A1 as a research target stems from:

• Its specific expression pattern throughout B-cell development (expressed by pre-B cells and maintained during all stages of B-cell maturation but lost during terminal differentiation into plasma cells)

• Its role in B-cell receptor signaling pathways

• Its established use as a diagnostic marker for B-cell lymphomas

• Its significance as a therapeutic target in B-cell malignancies and autoimmune disorders

MS4A1 belongs to the membrane-spanning 4A gene family, characterized by common structural features and similar intron/exon splice boundaries . This membrane protein contains four transmembrane domains and plays a critical role in store-operated calcium (SOC) channel activity, promoting calcium influx after B-cell receptor activation .

How should researchers select the appropriate MS4A1 antibody clone for their specific application?

Selection of an appropriate MS4A1 antibody clone should be methodically approached based on:

• Epitope location: Consider whether the experiment requires detection of extracellular or intracellular domains. For example, clone L26 recognizes an epitope in the cytoplasmic domain of CD20 , making it suitable for fixed cells/tissues, while other clones like IGEL/773 target recombinant human MS4A1 protein .

• Application compatibility: Verify validated applications for each clone:

  • L26 + IGEL/773: Effective for FC, IF, and IHC

  • UMAB38: Optimized for IHC (1:100) and WB (1:500)

  • 407CT20.1.2: Recommended for WB, IHC-P, and ELISA applications

• Species reactivity: Confirm cross-reactivity with your experimental model:

  • Some antibodies (like PB9050) react primarily with human samples

  • Others demonstrate broader reactivity across canine, human, porcine, primate, and rat samples

• Validation data: Examine available validation data, particularly for specificity testing in knockout models or using orthogonal methods .

What controls are essential when using MS4A1 antibodies in experimental protocols?

Implementing appropriate controls is crucial for reliable MS4A1 antibody experiments:

Positive controls:

• B lymphocyte cell lines (Ramos, Raji, or Daudi cells)

• Lymphoid tissues (tonsil, lymph nodes) with known B-cell populations

• Recombinant MS4A1 protein at known concentrations for quantitative assays

Negative controls:

• T-cell lines (though note that rare CD20+ T-cell populations have been reported)

• Non-lymphoid tissues lacking B-cells

• MS4A1/CD20 knockout samples when available

• Isotype-matched control antibodies (e.g., Mouse IgG1 for flow cytometry)

Additional controls for specific applications:

• For immunohistochemistry: Adjacent sections stained with secondary antibody only

• For flow cytometry: FMO (Fluorescence Minus One) controls with CD19+ gating to confirm B-cell specificity

• For functional studies: Include both rituximab (commercial anti-CD20) and isotype control antibodies

Researchers should document lot-to-lot variation and perform titration experiments to determine optimal antibody concentrations for each specific application and sample type.

What are the optimal protocols for using MS4A1 antibodies in immunohistochemistry?

Optimization of MS4A1 antibody protocols for immunohistochemistry requires attention to several key parameters:

For formalin-fixed, paraffin-embedded (FFPE) tissues:

• Antigen retrieval: Heat-induced epitope retrieval is typically necessary due to formalin fixation masking epitopes. Use citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) at 95-98°C for 20-30 minutes .

• Blocking: Apply 1-5% BSA or serum (from the same species as the secondary antibody) for 30-60 minutes at room temperature to minimize background staining .

• Primary antibody incubation: Dilute antibody according to validated recommendations (examples: clone UMAB38 at 1:100 , clone 407CT20.1.2 at 1:100-1:1000 ). Incubate overnight at 4°C or 1-2 hours at room temperature .

• Detection system: For mouse monoclonal antibodies, use appropriate HRP-conjugated anti-mouse secondary antibody systems. Vector Lab's Universal Anti-Mouse/Anti-Rabbit IgG is one validated option .

• Signal development: Use DAB (3,3'-diaminobenzidine) as a chromogen, monitoring until optimal signal-to-noise ratio is achieved .

Special considerations:

• MS4A1 antibodies may exhibit reduced reactivity in tissues fixed for extended periods (>24 hours)

• For double staining with other B-cell markers, sequential rather than simultaneous staining protocols are recommended

• When comparing normal and neoplastic tissues, standardize fixation times and processing methods to ensure comparable staining intensity

How can researchers optimize MS4A1 detection in flow cytometry experiments?

Flow cytometry optimization for MS4A1 detection requires attention to several critical factors:

• Sample preparation:

  • For peripheral blood: Use fresh samples when possible; if frozen, ensure viability assessment

  • For tissues: Generate single-cell suspensions using enzymatic digestion methods that preserve surface epitopes

  • Buffer selection: PBS with 1-2% BSA or FBS and 0.1% sodium azide maintains epitope integrity

• Antibody titration:

  • Perform serial dilutions (typically 1:10, 1:50, 1:100, 1:500) to identify optimal concentration

  • Calculate signal-to-noise ratio at each concentration

  • Select concentration that maximizes signal while minimizing background

• Panel design:

  • Include CD19 as a pan-B cell marker to properly identify B-cell populations

  • For lymphoma studies, include additional markers (CD5, CD10, CD23) to classify B-cell subsets

  • Select fluorophores based on expression level (brighter fluorophores for lower-expressed antigens)

• Gating strategy:

  • Begin with FSC/SSC to identify lymphocyte population

  • Apply singlet gating (FSC-H vs. FSC-A)

  • Gate on viable cells using appropriate viability dye

  • Identify CD19+ B cells before analyzing MS4A1/CD20 expression

• Controls:

  • Include isotype control (e.g., Mouse IgG1-APC for FAB4225A)

  • Use FMO (Fluorescence Minus One) controls for accurate gate placement

  • If possible, include known MS4A1-negative and MS4A1-positive populations

Example data from optimized MS4A1 detection by flow cytometry shows clear separation of positive and negative populations when human peripheral blood lymphocytes are stained with anti-CD19 PE and anti-MS4A1/CD20 APC antibodies .

What approaches can resolve inconsistent MS4A1 staining patterns in different sample types?

Inconsistent MS4A1 staining can arise from multiple factors that require systematic troubleshooting:

• Sample preparation variables:

  • Standardize fixation protocols: Overfixation can mask MS4A1 epitopes, while underfixation may compromise tissue morphology

  • For frozen sections: Acetone fixation (10 minutes at -20°C) often preserves MS4A1 epitopes better than formalin

  • For cell suspensions: Avoid harsh permeabilization reagents that may disrupt membrane epitopes

• Antibody-specific factors:

  • Epitope availability: Cytoplasmic domain-targeting antibodies (like L26) require effective permeabilization

  • Clone selection: Different clones recognize distinct epitopes with varying sensitivity to fixation

  • Consider antibody format: Some lyophilized antibodies require specific reconstitution protocols (e.g., UMAB38 requires reconstitution with distilled water to 1 mg/mL)

• Technical optimization:

  • Antigen retrieval modification: Test multiple methods (heat-induced vs. enzymatic) and buffers (citrate vs. EDTA)

  • Signal amplification: For low-expressing samples, implement tyramide signal amplification or similar techniques

  • Background reduction: Optimize blocking with 5% serum from secondary antibody species

• Sample-specific approaches:

  • For B-cell lymphomas: CD79a may serve as an alternative B-cell marker when MS4A1 staining is inconsistent

  • For circulating B cells: Fresh samples typically yield more consistent results than frozen

  • For tissues with high autofluorescence: Consider chromogenic detection instead of fluorescence

• Validation strategies:

  • Confirm staining pattern with alternative MS4A1 antibody clones

  • Verify MS4A1 expression using orthogonal methods (e.g., mRNA detection)

  • Implement dual-staining with other B-cell markers to confirm cellular identity

Researchers encountering variable staining should systematically document all protocol parameters and implement changes one at a time to identify the critical variables affecting staining consistency.

How is MS4A1 expression in T cells interpreted and validated in research studies?

The detection of MS4A1/CD20 in T cells, once considered anomalous, requires careful validation and interpretation:

Validation approaches:

• Multi-antibody verification: Use at least three different anti-MS4A1 antibodies targeting distinct epitopes to confirm staining pattern, as demonstrated in recent research that confirmed MS4A1 expression in non-lymphoid olfactory cells .

• Genetic verification: Employ knock-out models as negative controls to confirm antibody specificity. Antibodies should show no staining in MS4A1 knockout tissues .

• Transcriptional confirmation: Perform fluorescent in situ hybridization for MS4A1 mRNA in combination with protein detection (IHC) to verify that positive cells express both mRNA and protein .

• Cell sorting verification: Isolate putative MS4A1+ T cells by FACS and confirm lineage markers (CD3, TCR) and MS4A1 expression using orthogonal methods .

Interpretation guidance:
Analysis of scRNA-seq data has revealed that specific T cell subsets express MS4A1 at varying levels. Notable findings include:

• CD4-GZMK and CD8-GZMK T cells exhibit significantly higher MS4A1 expression levels

• CD4-CXCR5, CD4-IL23R, CD4-CXCL13, and CD4-CTLA4 T cells show significantly lower MS4A1 expression

• CD8-LEF1, CD8-CD6, CD8-CD160, and CD8-LAYN T cells display significantly lower MS4A1 expression

Researchers should note that CD20+ T cells represent a small population, which explains the "diminished sensitivity of scRNA-Seq analysis for low expression genes" . This underscores the importance of using sensitive detection methods when investigating MS4A1 in T cells.

What is the significance of MS4A1 expression in colorectal cancer, and how can it be leveraged in immunotherapy research?

Recent research has identified MS4A1 as a significant biomarker in colorectal cancer (CC) with implications for immunotherapy response prediction:

Key research findings:

Methodological approaches for investigating MS4A1 in CC:

• Expression analysis: Compare MS4A1 levels between tumor and adjacent tissues using:

  • Immunohistochemistry with validated antibodies

  • RNA-seq or qPCR for transcriptional profiling

  • Weighted gene co-expression network analysis (WGCNA) to identify gene modules associated with immune infiltration

• Correlation with immune infiltration:

  • Multiplex immunohistochemistry to co-localize MS4A1 with immune cell markers

  • Single-cell RNA sequencing to characterize MS4A1-expressing cells in the TME

  • Flow cytometry to quantify MS4A1+ cells in disaggregated tumor samples

• Functional studies:

  • Assess proliferation, migration, and invasion abilities of CC cells with varying MS4A1 expression levels

  • Correlate MS4A1 expression with response to immune checkpoint inhibitors

Translational implications:
MS4A1 and TNFRSF17 have been identified as potential biomarkers to predict sensitivity of CC patients to immunotherapy, particularly immune checkpoint inhibitors like anti-PD-1 and anti-PD-L1 . This suggests that MS4A1 expression profiling could be incorporated into patient selection strategies for immunotherapy trials in colorectal cancer.

How can researchers investigate the recently discovered role of MS4A1 in olfactory sensory neurons?

The unexpected discovery of MS4A1 expression in olfactory sensory neurons represents an emerging research area requiring specialized methodological approaches:

Validation methods:

• Multi-antibody verification:

  • Use multiple anti-MS4A1 antibodies targeting different epitopes

  • Ensure all antibodies co-label the same cells in the olfactory epithelium

  • Confirm antibody specificity using MS4A1 knockout mice as negative controls

• Transcriptional confirmation:

  • Implement combined fluorescent in situ hybridization for MS4A1 mRNA and immunohistochemistry

  • This approach allows verification that cells express both MS4A1 mRNA and protein

• Neuronal marker co-localization:

  • Co-stain with neuronal markers like NeuN to confirm neuronal identity

  • Verify that MS4A1-expressing cells do not express glial markers like KI18

Functional characterization approaches:

• Odor response experiments:

  • Test whether MS4A1-expressing olfactory sensory neurons respond to ligands known to activate MS4A receptors (e.g., 2,3-dimethylpyrazine, 2,5-DMP, oleic acid)

  • Employ calcium imaging to measure neuronal activation in response to odorants

• Behavioral assays:

  • Analyze innate odor-driven behaviors in wild-type versus MS4A1 knockout mice

  • Quantify avoidance behaviors in response to MS4A ligands

• Circuit mapping:

  • Trace axonal projections from MS4A1-expressing olfactory neurons to the olfactory bulb

  • Identify specific glomerular targets in the olfactory bulb

Anatomical considerations:
Research has shown that MS4A1-expressing cells in the olfactory epithelium extend sensory dendrites to the lumen of the main olfactory epithelium (MOE) and axonal-like structures toward the olfactory bulb . This morphology strongly suggests their function as true olfactory sensory neurons rather than supporting cells.

This newly discovered expression pattern represents an exciting area for future research that may reveal novel non-immune functions of MS4A1 in sensory perception.

What are the critical factors affecting MS4A1 antibody performance in western blotting experiments?

Western blotting for MS4A1 requires attention to several critical factors that impact antibody performance:

Sample preparation considerations:

• Membrane protein extraction: MS4A1 is a transmembrane protein associated with lipid rafts , requiring specialized extraction:

  • Use detergent-based lysis buffers containing 1% Triton X-100 or NP-40

  • Include protease inhibitors to prevent degradation

  • Avoid excessive heating that may cause protein aggregation

• Protein loading: MS4A1 has a predicted molecular weight of approximately 33 kDa , but may appear at different sizes:

  • Load sufficient protein (typically 20-50 μg total protein per lane)

  • Include positive control samples (B cell lines like Raji or Ramos)

  • Note that native MS4A1 may migrate differently than predicted due to its membrane nature

Protocol optimization:

• Transfer conditions: Optimize for membrane proteins:

  • Use PVDF membranes (rather than nitrocellulose) for better retention

  • Consider semi-dry transfer at lower voltage for longer time

  • Include methanol in transfer buffer to improve protein binding

• Antibody selection and dilution:

  • Choose antibodies validated for WB (e.g., UMAB38 at 1:500 dilution)

  • For C-terminal epitopes, use antibodies like 407CT20.1.2 (targeting aa 266-294)

  • Optimize primary antibody concentration through titration experiments

• Signal detection:

  • Use enhanced chemiluminescence systems for optimal sensitivity

  • Consider longer exposure times if signal is weak

  • For quantification, ensure linear dynamic range of detection

Troubleshooting guidance:

• Multiple bands: May indicate isoforms, degradation products, or non-specific binding:

  • Verify with antibodies targeting different epitopes

  • Use MS4A1 knockout or knockdown samples as negative controls

  • Consider alternative validation methods like immunoprecipitation

• No signal detected:

  • Verify B-cell marker expression (e.g., CD19) to confirm sample identity

  • Assess protein extraction efficiency using membrane protein controls

  • Test alternative antibody clones or epitope targets

• Unexpected size:

  • MS4A1 may form dimers or multimers in certain conditions

  • Post-translational modifications may alter migration pattern

  • Some sample preparation methods may cause incomplete denaturation

How should researchers address contradictory MS4A1 expression data between different detection methods?

When facing contradictory MS4A1 expression data across different detection platforms, researchers should implement a systematic evaluation approach:

Assessment framework:

• Method-specific limitations evaluation:

  • IHC/IF: May be affected by epitope availability, fixation artifacts, or antibody specificity

  • Flow cytometry: Cell preparation can damage surface epitopes; gating strategy influences interpretation

  • Western blot: Membrane protein extraction efficiency varies; detection sensitivity differs by antibody

  • qPCR/RNA-seq: Measures transcript levels which may not correlate with protein abundance

• Sample-specific considerations:

  • Fresh vs. fixed tissues: MS4A1 epitopes may be differentially preserved

  • Cell lines vs. primary cells: Expression levels and regulation can differ significantly

  • Normal vs. malignant cells: MS4A1 expression patterns can be altered in malignancy

• Systematic validation approach:

  • Start with orthogonal methods targeting the same samples

  • Use both protein and RNA detection methods when possible

  • Implement positive and negative controls for each method

  • Consider subcellular localization (membrane vs. cytoplasmic detection)

Resolution strategies:

• Technical reconciliation:

  • For RNA vs. protein discrepancies: Assess post-transcriptional regulation or protein stability

  • For antibody-based methods: Compare epitopes targeted by different antibodies

  • For visualization techniques: Consider detection sensitivity thresholds

• Biological interpretation:

  • MS4A1 expression varies by B-cell developmental stage (lost upon terminal differentiation to plasma cells)

  • Expression can be altered in pathological states

  • Different B-cell subpopulations show variable MS4A1 expression levels

• Documentation practices:

  • Clearly specify detection method, antibody clone, and protocol details in publications

  • Report quantitative measures with appropriate statistical analysis

  • Acknowledge limitations of each technique used

How can researchers distinguish between true MS4A1 expression in unusual cell types versus antibody cross-reactivity?

Distinguishing genuine MS4A1 expression from antibody cross-reactivity, particularly in unusual cell types like T cells or olfactory neurons, requires a comprehensive validation approach:

Multi-level validation framework:

• Antibody validation tier:

  • Multiple independent antibodies: Test at least three different antibodies targeting distinct epitopes of MS4A1, as demonstrated in olfactory neuron studies

  • Knockout controls: Confirm complete absence of staining in MS4A1 knockout tissues

  • Peptide competition: Pre-absorb antibody with immunizing peptide to demonstrate specificity

  • Isotype controls: Use matched isotype antibodies to identify non-specific binding

• Transcript verification tier:

  • mRNA detection: Perform in situ hybridization for MS4A1 mRNA in the same cell types

  • RT-PCR: Extract RNA from sorted cell populations to verify MS4A1 transcript presence

  • RNA-seq validation: Analyze single-cell RNA-seq data for MS4A1 expression in the cell type of interest

  • Primer specificity: Design primers spanning exon-exon junctions to avoid genomic DNA contamination

• Functional validation tier:

  • Protein-protein interactions: Demonstrate expected interactions of MS4A1 in the unusual cell type

  • Functional assays: Show calcium signaling responses consistent with MS4A1 function

  • Knockdown effects: Evaluate phenotypic changes following MS4A1 silencing

Interpretation guidelines:

When assessing unusual MS4A1 expression, researchers should carefully document:

• Expression levels relative to B cells (typically lower in non-B cells)

• Subcellular localization (membrane expression consistent with MS4A1's known topology)

• Co-expression with lineage-specific markers (to confirm cell identity)

• Functional relevance in the specific cell type

Recent research has confirmed legitimate MS4A1 expression in select T cell subsets and olfactory sensory neurons using these rigorous approaches, expanding our understanding of this protein beyond its classical B-cell expression pattern.

How can MS4A1 function as a calcium channel be investigated in experimental models?

Investigating MS4A1's role as a store-operated calcium (SOC) channel requires specialized techniques to measure calcium dynamics and channel function:

Cellular calcium imaging approaches:

• Fluorescent calcium indicators:

  • Load cells with ratiometric calcium indicators (Fura-2/AM) or single-wavelength indicators (Fluo-4)

  • Measure baseline calcium levels and changes following B-cell receptor (BCR) stimulation

  • Compare calcium responses between MS4A1-expressing and MS4A1-knockout/knockdown cells

• Genetically encoded calcium indicators (GECIs):

  • Express GCaMP or similar calcium sensors in B cells or MS4A1-transfected cell lines

  • Enables longer-term imaging without dye leakage issues

  • Can be targeted to specific subcellular compartments to distinguish ER and cytosolic calcium

• Patch-clamp electrophysiology:

  • Directly measure calcium currents using whole-cell or single-channel configurations

  • Compare conductance properties between wild-type and mutant MS4A1 variants

  • Evaluate channel pharmacology using calcium channel modulators

Functional manipulation strategies:

• Site-directed mutagenesis:

  • Generate MS4A1 mutants with altered transmembrane domains

  • Assess impact on calcium influx following BCR activation

  • Identify critical residues for channel function

• Pharmacological approaches:

  • Apply calcium channel blockers or modulators

  • Test rituximab or other anti-CD20 antibodies for effects on calcium signaling

  • Use store-operated calcium entry (SOCE) inhibitors to determine pathway specificity

• Molecular interaction studies:

  • Investigate MS4A1 interactions with other SOCE components (STIM1, Orai1)

  • Perform co-immunoprecipitation or proximity ligation assays

  • Examine effects of MS4A1 clustering on calcium channel assembly

Experimental readouts:
Researchers should measure multiple parameters including:

• Peak calcium response amplitude

• Calcium oscillation frequency

• Sustained calcium plateau duration

• Store-operated calcium entry kinetics

• Calcium-dependent downstream signaling (e.g., NFAT translocation, PLC-γ phosphorylation)

These approaches will help elucidate how MS4A1 "functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR" , advancing our understanding of its role in B-cell activation and potential therapeutic targeting.

What are the latest methodologies for targeting MS4A1 in therapeutic antibody development research?

Current methodologies for developing next-generation MS4A1-targeting therapeutic antibodies focus on enhancing efficacy and addressing resistance mechanisms:

Antibody engineering approaches:

• Epitope optimization:

  • Target specific MS4A1 epitopes to enhance complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC)

  • Develop antibodies binding MS4A1 epitopes distinct from rituximab binding sites to overcome resistance

  • Generate antibodies recognizing MS4A1 conformational changes during calcium channel function

• Affinity maturation:

  • Implement directed evolution methods to enhance binding affinity

  • Use structural biology insights to design complementarity-determining regions (CDRs)

  • Optimize on/off rates for improved tumor penetration and retention

• Fc engineering:

  • Modify Fc regions to enhance interactions with Fcγ receptors on effector cells

  • Introduce mutations that improve complement activation

  • Develop bispecific formats targeting MS4A1 and immune effector cells

Functional screening methodologies:

• In vitro efficacy assays:

  • Cell viability assays without antibody cross-linking (direct apoptosis induction)

  • Annexin V/PI apoptosis detection to quantify programmed cell death

  • CDC assays measuring complement-mediated lysis

  • ADCC assays evaluating NK cell-mediated target cell killing

• In vivo evaluation models:

  • Ramos i.v. paralysis model (CB17 SCID mice) for survival benefit assessment

  • Daudi subcutaneous tumor model for measuring tumor volume reduction

  • Patient-derived xenograft models for evaluating efficacy against primary clinical samples

• Resistance mechanism assessment:

  • Loss of surface MS4A1 expression

  • Internalization kinetics of antibody-MS4A1 complexes

  • Complement resistance mechanisms

Advanced production platforms:
Modern therapeutic antibody development utilizes:

• Recombinant antibody technologies with benefits including increased sensitivity, confirmed specificity, high repeatability, and excellent batch-to-batch consistency

• Animal-free production systems for sustainable supply

• Format diversification (ADCs, bispecifics, CAR constructs) targeting MS4A1